The decision to pause the investment in Cambridge, one of the UK’s most important life sciences hubs, which had been expected to create 1,000 jobs, means that none of AstraZeneca’s planned projects in the country are currently moving forward.
“We constantly reassess the company’s investment needs and can confirm that our expansion in Cambridge is paused. We have no further comment,” a spokesperson told Reuters.